IMVT

The Law Offices of Frank R. Cruz Announces Investigation of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT) on Behalf of Investors

Tuesday, February 23, 2021 - 6:00pm

The Law Offices of Frank R. Cruz announces an investigation of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ("HSAC", "Immunovant", or the Company) (NASDAQ: IMVT ) on behalf of investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • The Law Offices of Frank R. Cruz announces an investigation of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ("HSAC", "Immunovant", or the Company) (NASDAQ: IMVT ) on behalf of investors concerning the Companys possible violations of federal securities laws.
  • On February 2, 2021, the Company issued a press release announc[ing] a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401.
  • On this news, the Companys stock price fell $18.22 per share, or 42.08%, to close at $25.08 per share on February 2, 2021, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT) on Behalf of Investors

Tuesday, February 23, 2021 - 1:17am

Law Offices of Howard G. Smith announces an investigation on behalf of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ("HSAC", "Immunovant", or the Company) (NASDAQ: IMVT ) investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith announces an investigation on behalf of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ("HSAC", "Immunovant", or the Company) (NASDAQ: IMVT ) investors concerning the Companys possible violations of federal securities laws.
  • On February 2, 2021, the Company issued a press release announc[ing] a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401.
  • On this news, the Companys stock price fell $18.22 per share, or 42.08%, to close at $25.08 per share on February 2, 2021, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401

Tuesday, February 2, 2021 - 11:30am

NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401.

Key Points: 
  • NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401.
  • Cholesterol levels were not measured in prior clinical trials of IMVT-1401 in Myasthenia Gravis (MG) and in healthy subjects.
  • In this study, cholesterol parameters are assessed at baseline, at twelve weeks, and at week 20 following eight weeks off drug.
  • Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Ligand OmniAb® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis

Tuesday, August 25, 2020 - 9:15pm

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) OmniAb partner Immunovant, Inc. (NASDAQ: IMVT) announced positive topline results from ASCEND MG, a Phase 2a study of OmniAb-derived IMVT-1401 in patients with myasthenia gravis (MG).

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) OmniAb partner Immunovant, Inc. (NASDAQ: IMVT) announced positive topline results from ASCEND MG, a Phase 2a study of OmniAb-derived IMVT-1401 in patients with myasthenia gravis (MG).
  • We are proud of the ongoing work by Immunovant and the strong results demonstrated by IMVT-1401 in patients who suffer with myasthenia gravis.
  • We have a growing OmniAb partner base with an increasing number of late-stage programs with important upcoming clinical or regulatory events.
  • Immunovant plans to initiate a Phase 3 registration study with IMVT-1401 for the treatment of myasthenia gravis in the first half of 2021.

Immunovant Announces Positive Topline Results from Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Myasthenia Gravis

Tuesday, August 25, 2020 - 12:30pm

Results from the six-week treatment period included three arms: 340 mg IMVT-1401 weekly (N=5), 680 mg IMVT-1401 weekly (N=5), and placebo (N=5).

Key Points: 
  • Results from the six-week treatment period included three arms: 340 mg IMVT-1401 weekly (N=5), 680 mg IMVT-1401 weekly (N=5), and placebo (N=5).
  • MG-ADL responder rates, defined as the percentage of patients showing a > 2-point improvement, were 60% for IMVT-1401-treated patients vs. 20% for placebo.
  • We are absolutely thrilled with the results of this trial, said Pete Salzmann, M.D., Chief Executive Officer of Immunovant.
  • Importantly, IMVT-1401 was delivered by subcutaneous injection, opening the future possibility of at-home, self-administered treatment rather than infusion center-based treatment.

Immunovant Sciences Ltd. Closes Transaction with Health Sciences Acquisitions Corporation

Thursday, December 19, 2019 - 1:00pm

HSAC reported that, prior to the special meeting, there were zero redemptions from HSAC shareholders, an uncommon occurrence demonstrating the strength of the transaction.

Key Points: 
  • HSAC reported that, prior to the special meeting, there were zero redemptions from HSAC shareholders, an uncommon occurrence demonstrating the strength of the transaction.
  • The combined company was renamed Immunovant, Inc. (Immunovant), and Immunovants shares of common stock are expected to begin trading on Nasdaq under the symbol IMVT on December 19, 2019.
  • ISLs management team will continue to run Immunovant, led by Chief Executive Officer, Pete Salzmann, M.D.
  • Proceeds from this transaction exceeded $100 million and will provide Immunovant with capital expected to progress three key IMVT-1401 pipeline programs for Graves ophthalmopathy, myasthenia gravis, and warm autoimmune hemolytic anemia.

Immunovant Appoints Robert K. Zeldin, M.D. as Chief Medical Officer and W. Bradford Middlekauff, J.D. as General Counsel

Tuesday, August 13, 2019 - 1:00pm

A clinical immunologist by training, Dr. Zeldin brings over two decades of clinical, regulatory and industry experience to Immunovant.

Key Points: 
  • A clinical immunologist by training, Dr. Zeldin brings over two decades of clinical, regulatory and industry experience to Immunovant.
  • I am delighted to welcome him as we pursue studies of IMVT-1401 for multiple autoimmune diseases," said Pete Salzmann, M.D., Chief Executive Officer of Immunovant.
  • "IMVT-1401 is a promising subcutaneous product candidate with the potential to treat a number of serious and rare diseases with significant unmet medical need.
  • A graduate of Yale Law School, Mr. Middlekauff brings over twenty-five years of legal, business and industry experience to Immunovant.